Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2009 DRUG RECALL DATA ANALYZED BY DOSAGE FORM

This article was originally published in The Gold Sheet

Executive Summary

The following is an analysis by dosage form of the data on drug recalls included in FDA "Enforcement Reports" during 2009. The chart includes the number of products recalled for each dosage form by market type (Rx vs. OTC), problem area and recall class. [EDITOR'S NOTE: See the head note of "Drug Product Recalls In 2009: Categorized By Problem Area" for more information on the recall data and categories.]

You may also be interested in...



Drug Product Recalls In 2009: Categorized By Problem Area

The information on drug product recalls in the following pages has been collected and categorized by "The Gold Sheet" from FDA "Enforcement Reports" issued during calendar year 2009.

McKinsey Survey Highlights Progress, Challenges in Adoption of QbD

Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.

Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD

Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel